Glutamine antagonists may KEAP lung cancer in check

Eliot B Blatt; Ralph J DeBerardinis

doi:10.1126/sciadv.ado7808

Glutamine antagonists may KEAP lung cancer in check

Sci Adv. 2024 Mar 29;10(13):eado7808. doi: 10.1126/sciadv.ado7808. Epub 2024 Mar 27.

Authors

Eliot B Blatt¹, Ralph J DeBerardinis^{1

2}

Affiliations

¹ Children's Research Institute, UT Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, TX 75390, USA.
² Howard Hughes Medical Institute, UT Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, TX 75390, USA.

Abstract

The glutamine antagonist DRP-104 blocks purine synthesis and combines with checkpoint inhibitors to promote antitumor immunity in KEAP1/NRF2-mutant lung cancers.

Publication types

Review

MeSH terms

Glutamine
Humans
Kelch-Like ECH-Associated Protein 1
Lung Neoplasms* / drug therapy
Lung Neoplasms* / pathology
NF-E2-Related Factor 2 / metabolism

Substances

Kelch-Like ECH-Associated Protein 1
Glutamine
NF-E2-Related Factor 2